|
|
| (One intermediate revision not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of a polysaccharide-binding human Fab (F598) in complex with N-acetyl-D-glucosamine (GlcNAc)== | | ==Crystal structure of a polysaccharide-binding human Fab (F598) in complex with N-acetyl-D-glucosamine (GlcNAc)== |
| - | <StructureSection load='6be3' size='340' side='right' caption='[[6be3]], [[Resolution|resolution]] 1.60Å' scene=''> | + | <StructureSection load='6be3' size='340' side='right'caption='[[6be3]], [[Resolution|resolution]] 1.60Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6be3]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BE3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BE3 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6be3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BE3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6BE3 FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.6Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6be2|6be2]], [[6be4|6be4]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6be3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6be3 OCA], [http://pdbe.org/6be3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6be3 RCSB], [http://www.ebi.ac.uk/pdbsum/6be3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6be3 ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6be3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6be3 OCA], [https://pdbe.org/6be3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6be3 RCSB], [https://www.ebi.ac.uk/pdbsum/6be3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6be3 ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 21: |
Line 21: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Ramsland, P A]] | + | [[Category: Large Structures]] |
| - | [[Category: Soliman, C]] | + | [[Category: Ramsland PA]] |
| - | [[Category: Antigen binding fragment]] | + | [[Category: Soliman C]] |
| - | [[Category: Complex]]
| + | |
| - | [[Category: Human antibody]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Immunoglobulin]]
| + | |
| - | [[Category: N-acetyl-d-glucosamine]]
| + | |
| Structural highlights
Publication Abstract from PubMed
In response to the widespread emergence of antibiotic-resistant microbes, new therapeutic agents are required for many human pathogens. A non-mammalian polysaccharide, poly-N-acetyl-D-glucosamine (PNAG), is produced by bacteria, fungi, and protozoan parasites. Antibodies that bind to PNAG and its deacetylated form (dPNAG) exhibit promising in vitro and in vivo activities against many microbes. A human IgG1 mAb (F598) that binds both PNAG and dPNAG has opsonic and protective activities against multiple microbial pathogens and is undergoing preclinical and clinical assessments as a broad-spectrum antimicrobial therapy. Here, to understand how F598 targets PNAG, we determined crystal structures of the unliganded F598 antigen-binding fragment (Fab) and its complexes with N-acetyl-D-glucosamine (GlcNAc) and a PNAG oligosaccharide. We found that F598 recognizes PNAG through a large groove-shaped binding site that traverses the entire light- and heavy-chain interface and accommodates at least five GlcNAc residues. The Fab-GlcNAc complex revealed a deep binding pocket in which the monosaccharide and a core GlcNAc of the oligosaccharide were almost identically positioned, suggesting an anchored binding mechanism of PNAG by F598. The Fab used in our structural analyses retained binding to PNAG on the surface of an antibiotic-resistant, biofilm-forming strain of Staphylococcus aureus Additionally, a model of intact F598 binding to two pentasaccharide epitopes indicates that the Fab arms can span at least 40 GlcNAc residues on an extended PNAG chain. Our findings unravel the structural basis for F598 binding to PNAG on microbial surfaces and biofilms.
Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetyl glucosamine.,Soliman C, Walduck AK, Yuriev E, Richards JS, Cywes-Bentley C, Pier GB, Ramsland PA J Biol Chem. 2018 Feb 15. pii: RA117.001170. doi: 10.1074/jbc.RA117.001170. PMID:29449370[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Soliman C, Walduck AK, Yuriev E, Richards JS, Cywes-Bentley C, Pier GB, Ramsland PA. Structural basis for antibody targeting of the broadly expressed microbial polysaccharide poly-N-acetyl glucosamine. J Biol Chem. 2018 Feb 15. pii: RA117.001170. doi: 10.1074/jbc.RA117.001170. PMID:29449370 doi:http://dx.doi.org/10.1074/jbc.RA117.001170
|
